Clinical features of newly diagnosed systemic lupus erythematosus after SARS-CoV-2 vaccination

Mod Rheumatol Case Rep. 2023 Dec 29;8(1):63-68. doi: 10.1093/mrcr/rxad036.

Abstract

Systemic lupus erythematosus (SLE) is an autoimmune disease that causes damage to multiple organs. Various factors, including vaccination, have been associated with SLE development. Vaccination for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) began in 2020, and there are a few reports on the exacerbation of SLE after SARS-CoV-2 vaccination. The influence of SARS-CoV-2 vaccination on SLE development remains unclear. We present the case of a 53-year-old man who developed peritonitis and was subsequently diagnosed with SLE on Day 9 after receiving a third dose of the messenger ribonucleic acid-1273 SARS-CoV-2 vaccine. This case and previous reports have shown that patients who developed SLE after SARS-CoV-2 vaccination are more likely to develop it within 2 weeks of vaccination, especially when they have a higher rate of immunological abnormalities or a family history of autoimmune diseases. Furthermore, these features suggest that type I interferon is involved in the pathogenesis of SLE after SARS-CoV-2 vaccination.

Keywords: COVID-19; SARS-CoV-2; Systemic lupus erythematosus; interferon type I; vaccination.

Publication types

  • Case Reports

MeSH terms

  • Autoimmune Diseases*
  • COVID-19 Vaccines* / adverse effects
  • COVID-19* / diagnosis
  • COVID-19* / prevention & control
  • Humans
  • Lupus Erythematosus, Systemic* / complications
  • Lupus Erythematosus, Systemic* / diagnosis
  • Male
  • Middle Aged
  • SARS-CoV-2
  • Vaccination / adverse effects

Substances

  • COVID-19 Vaccines